Home › Funds › Fideuram Asset Management (Ireland) dac › NBIX

Fideuram Asset Management (Ireland) dac position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

Fideuram Asset Management (Ireland) dac reported holding 127,301 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$20.9M, representing 0.46% of its reported portfolio and ranking #38 among its reported holdings. Fideuram Asset Management (Ireland) dac has disclosed NBIX holdings in 3 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)127.30K sh
Reported value held$20.88M
Portfolio Weight0.46%
First reportedQ4 2025
Last changeAdd
Updated2026-10-29

Last updated: 2026-10-29 · Source: SEC EDGAR Form 13F-HR

How Fideuram Asset Management (Ireland) dac's NBIX position evolved

Fideuram Asset Management (Ireland) dac first disclosed a stake in NBIX in Q4 2025 at 19 shares (US$3K). The position peaked in Q3 2026 at 127,301 shares, worth US$20.9M. Across 3 filings, Fideuram Asset Management (Ireland) dac increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 127,301 shares valued at US$20.9M — an increase of 122,379 shares quarter over quarter.. Notable position changes include a 2486% increase in Q3 2026 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 19 $2.71K New
Q2 2026 4.92K $796.36K New
Q3 2026 127.30K $20.88M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 34 other funds we track also report a position in NBIX — the largest reported positions include Renaissance Technologies (US$393.7M), Two Sigma Investments (US$349.9M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has Fideuram Asset Management (Ireland) dac held NBIX?

Fideuram Asset Management (Ireland) dac has disclosed NBIX holdings in 3 of the last 4 reported quarters, going back to Q4 2025.

What is Fideuram Asset Management (Ireland) dac's current position in NBIX?

As of Q3 2026, Fideuram Asset Management (Ireland) dac holds 127.30K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $20.88M, representing 0.46% of its reported portfolio and ranking #38.

Has Fideuram Asset Management (Ireland) dac been buying or selling NBIX?

In the latest 13F filing (Q3 2026), Fideuram Asset Management (Ireland) dac increased its position in NBIX. The position peaked in Q3 2026 at 127.30K shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Renaissance Technologies, Two Sigma Investments, Vestal Point Capital, LP, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.